Amplifon S.p.A (AMP) Fair Value & Analysis
Healthcare · IT · Market cap €2.8B
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 5 days ago
Share price −12.3% over the past month.
Price vs Fair Value (12 months)
12‑month range €8.39 – €21.36 · fair‑value band €5.68 – €9.47 · the €10.15 price screens above the €7.58 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Amplifon S.p.A (AMP) currently trades at €10.15, while our model-based Fair Value estimate is €7.58 — implying the stock looks roughly 25.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Amplifon S.p.A generated revenue of €2.4B at a net margin of 2.9%. Revenue declined 1.4% year over year. It earns a return on equity of 6.2%. Net debt stands at €1.0B. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Amplifon S.p.A. distributes hearing solutions and the fitting of customized products that helps people to rediscover various emotions of sound in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. It operates Ampli-care, a platform to deliver audiological care experience; and Amplifon App to manage the device functions in real-time directly from smartphone. The company also offers Ampli-power and Ampli-mini hearing devices. Amplifon S.p.A. was founded in 1950 and is headquartered in Milan, Italy.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Amplifon S.p.A reported revenue of €2.4B in FY2025 versus €1.9B in FY2021, a compound +5.3%/yr. Reported net income was €91.3M in FY2025, compounding −12.8%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation M1CK34 | R$958.36 | R$188.90 | -80% |
| Cencora, Inc C1CO34 | R$707.04 | R$79.88 | -89% |
| Cardinal Health, Inc CAH | $222.74 | $141.77 | -36% |
| Sigma Healthcare Limited SIGGF | $2.35 | $0.6300 | -73% |
| Sitka Gold Corp SIG | A$2.92 | A$1.20 | -59% |
| Shanghai Pharmaceuticals Holding 601607 | ¥15.96 | ¥45.15 | +183% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Amplifon S.p.A (AMP) undervalued?
What is the fair value of AMP?
What is the quality score of AMP?
What is the revenue of Amplifon S.p.A (AMP)?
What is the net profit margin of AMP?
Does Amplifon S.p.A pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.